Unlocking The Potential of SPATA42: A Non-Coding RNA Molecule as A Drug Target and Biomarker

Target Name: SPATA42

NCBI ID: G642864

SPATA42

Other Name(s): SRG7 | spermatogenesis associated 42 | SPATA42 variant 1 | Spermatogenesis associated 42, transcript variant 1 | AKNAD1-AS1

Unlocking The Potential of SPATA42: A Non-Coding RNA Molecule as A Drug Target and Biomarker

SPATA42 (SRG7) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed new light on its role in various biological processes.

The story of SPATA42 began in the early 1990s when researchers identified a family of non-coding RNAs (ncRNAs) that were highly expressed in various tissues, including the brain. These ncRNAs, known as microRNAs (miRNAs), were found to have unique functions , including regulating gene expression, predicting the structure of RNA molecules, and modulating cellular processes.

One of the most promising miRNA candidates was SPATA42, which was identified in the brain and other tissues. SPATA42 is a short RNA molecule that contains 75 amino acid residues. Its unique structure consists of a long terminal region, a stem-loop region, and a unique 3' end that contains a single RNA structure.

SPATA42 has been shown to play a critical role in various cellular processes, including cell growth, differentiation, and apoptosis (programmed cell death). It has been shown to regulate the expression of genes involved in cell adhesion, migration, and invasion, as well as in the regulation of the blood-brain barrier.

SPATA42 has also been shown to be involved in the regulation of pain perception and the modulation of neurotransmitter systems. It has been shown to interact with various partners protein, including the protein SMY/TAZ, which is involved in the regulation of pain perception and neurotransmitter systems.

SPATA42 has also been shown to be involved in the regulation of cell cycle progression, and it has been shown to interact with the protein kinase PDK4. This interaction between SPATA42 and PDK4 has been shown to play a critical role in the regulation of cell growth, apoptosis, and the progression of cancer.

SPATA42 has also been shown to be involved in the regulation of stem cell maintenance and proliferation. It has been shown to interact with the protein SXP7, which is involved in the regulation of stem cell proliferation and differentiation.

SPATA42 has also been shown to be involved in the regulation of tissue repair and regeneration. It has been shown to interact with the protein TGF-β, which is involved in the regulation of tissue repair and regeneration.

SPATA42 has also been shown to be involved in the regulation of the immune response. It has been shown to interact with the protein NF-kappa-B, which is involved in the regulation of inflammation and immune responses.

SPATA42 has also been shown to be involved in the regulation of the blood-brain barrier. It has been shown to interact with the protein ABCG2, which is involved in the regulation of the blood-brain barrier.

SPATA42 has also been shown to be involved in the regulation of the nervous system. It has been shown to interact with the protein Parp, which is involved in the regulation of DNA damage repair and neurodegeneration.

SPATA42 has also been shown to be involved in the regulation of the endoplasmic reticulum. It has been shown to interact with the protein TRPV4, which is involved in the regulation of neurotransmitter release from the endoplasmic reticulum.

SPATA42 has also been shown to be involved in the regulation of the cytoskeleton. It has been shown to interact with the protein tubulin 2 (MTOR), which is involved in

Protein Name: Spermatogenesis Associated 42

The "SPATA42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPATA42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets